CN116178512B - 一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 - Google Patents
一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 Download PDFInfo
- Publication number
- CN116178512B CN116178512B CN202310192513.6A CN202310192513A CN116178512B CN 116178512 B CN116178512 B CN 116178512B CN 202310192513 A CN202310192513 A CN 202310192513A CN 116178512 B CN116178512 B CN 116178512B
- Authority
- CN
- China
- Prior art keywords
- cry
- polypeptide
- protein
- toxin
- gxjg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 70
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 31
- 108700003918 Bacillus Thuringiensis insecticidal crystal Proteins 0.000 title claims abstract description 18
- 108700012359 toxins Proteins 0.000 claims abstract description 67
- 239000003053 toxin Substances 0.000 claims abstract description 58
- 231100000765 toxin Toxicity 0.000 claims abstract description 58
- 230000002163 immunogen Effects 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 241000255967 Helicoverpa zea Species 0.000 claims abstract description 11
- 239000002773 nucleotide Substances 0.000 claims abstract description 10
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 45
- 241000607479 Yersinia pestis Species 0.000 abstract description 17
- 238000001514 detection method Methods 0.000 abstract description 16
- 241000699670 Mus sp. Species 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 8
- 230000000749 insecticidal effect Effects 0.000 abstract description 4
- 102000000905 Cadherin Human genes 0.000 abstract description 3
- 108050007957 Cadherin Proteins 0.000 abstract description 3
- 230000009465 prokaryotic expression Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- 230000006870 function Effects 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 241000238631 Hexapoda Species 0.000 description 10
- 238000009739 binding Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 240000000220 Panda oleosa Species 0.000 description 6
- 235000016496 Panda oleosa Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000193388 Bacillus thuringiensis Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940097012 bacillus thuringiensis Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 230000004001 molecular interaction Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001147381 Helicoverpa armigera Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000012482 interaction analysis Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010089921 CTCGAG-specific type II deoxyribonucleases Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101150102464 Cry1 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010013216 GATATC-specific type II deoxyribonucleases Proteins 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710151559 Crystal protein Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000001999 Transcription Factor Pit-1 Human genes 0.000 description 1
- 108010040742 Transcription Factor Pit-1 Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010073357 cyanoginosin LR Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000463 ecotoxicology Toxicity 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 description 1
- DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P7/00—Arthropodicides
- A01P7/04—Insecticides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pest Control & Pesticides (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Dentistry (AREA)
- Physics & Mathematics (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种具备模拟Bt Cry毒素抗虫蛋白共性结构的多肽及其编码基因与应用,该多肽核苷酸序列、氨基酸序列分别如SEQ ID NO.1、SEQ ID NO.2所示;该多肽能与Bt Cry毒素靶标害虫棉铃虫钙黏蛋白受体特异性结合,且经原核表达后的多肽蛋白对供试的棉铃虫具有良好的杀虫活性,以其为免疫原免疫小鼠获得的血清能同时识别6种Bt Cry毒素;本申请提供的具备模拟Bt Cry毒素共性结构和功能的多肽在替代Bt Cry毒素抗虫蛋白用于靶标农业害虫绿色防治和作为免疫原用于高效制备Bt Cry毒素检测用广谱抗体方面具有重要的科学意义和广阔的应用价值。
Description
技术领域
本发明涉及抗虫蛋白生物防治和免疫学检测技术领域,特别是一种模拟Bt Cry毒素抗虫蛋白共性结构和功能的多肽及其编码基因与应用。
背景技术
Bt Cry毒素是苏云金芽孢杆菌(Bacillus thuringiensis,Bt)代谢产生的一类对鳞翅目、鞘翅目等常见农业害虫具有特异性高致死活性的伴孢晶体蛋白,其主要通过抑制靶标害虫中肠受体如钙黏蛋白、腺苷三磷酸结合盒转运蛋白、氨肽酶、碱性磷酸酶等特殊功能蛋白或酶的活性,诱发一系列信号传导,造成中肠细胞穿孔,从而导致害虫死亡。根据国际Bt毒素抗虫蛋白数据库权威网站(http://www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/)发布信息,截止目前,已发现并命名的Bt Cry毒素有78个基因家族(Cry1~Cry78),基因亚型共计818个。
Bt Cry毒素是目前研究最深入、应用最广泛的生物抗虫蛋白,其制剂以及转基因抗虫作物在全球农业病虫害绿色防治上发挥着引领作用,产生了巨大的经济和社会效益。根据国际农业生物技术应用服务组织(International Service for the AcquisitionofAgri-biotechApplications,ISAAA)最新统计数据,目前全球推广种植的转Bt Cry毒素基因抗虫农作物年均超过1亿公顷,农产品增产价值接近190亿美元。然而,随着Bt Cry毒素制剂及其转基因抗虫作物长期大范围推广应用,由其诱发产生的靶标害虫非正常抗药性进化频率加剧以及严重威胁非靶标生物安全等问题日益凸显(“Mechanisms ofResistanceto Insecticidal Proteins from Bacillus thuringiensis”,J.Jurat-Fuentes等,Annual Review ofEntomology,2021年,总第66期;“Ahistorical overview ofanalysissystems for Bacillus thuringiensis(Bt)Cryproteins”,J.Gu等,MicrochemicalJournal,2021年,总第165期)。
此外,转Bt Cry毒素基因抗虫作物在目标生物体对药物产生耐受性、基因跨物种逃逸、微生态生物多样性结构失衡以及伤害非目标生物的免疫系统等方面,可能存在安全隐患。文献“转Bt基因玉米根际微生物和细菌生理群多样性”(王敏等,生态学杂志,2010年03期)和“转Bt基因玉米对土壤细菌数量多样性的影响”(刘玲等,生态与农村环境学报,2011年03期)分别对室内、室外种植转Bt玉米的土壤进行了细菌数量和多样性分析,结果都发现种植转Bt玉米的与空白对照组相比出现显著差异。文献“Cry1Ac protoxin fromBacillus thuringiensis sp.kurstaki HD73 binds to surface proteins in themouse small intestine”(Vázquez-Padrón等,Biochem Biophys Res Commun,2000年01期)在动物试验发现,当小鼠摄取的Bt内、外毒素达到10mg/kg和100mg/kg时,小鼠的T细胞ANAE阳性率、脾脏指数及巨噬细胞的吞噬功能均出现了明显的抑制反应,随着摄取剂量的增加,这种抑制作用越发明显。试验还发现,当Bt毒素蛋白在动物体内的蓄积系数大于6.24时,可以导致肝脏、肾脏及胃肠道等损伤,在肝脏和肾脏中可以观察到细胞肿胀和空泡样变性异象,并且能看见肾小球血管上皮细胞的病变。长期大剂量使用Bt毒素蛋白,还会导致动物白细胞总数和血红蛋白含量显著性下降,这也说明Bt毒素蛋白具有明显的免疫抑制毒性。因此探寻Bt Cry毒素抗虫功能效应物以及对其筛查与追踪检测用的创新技术具有重要的科学意义和广阔的市场应用前景。
在探寻Bt Cry毒素功能效应物方面,由于Bt Cry毒素蛋白三维结构一般由DomianI、Domian II、Domian III三个结构域组成,早期较为传统的方式是以Bt Cry毒素为模板,采用不同亚型的结构域或功能片段融合替换,实现具有更强抗虫活性或更广抗虫谱系的新型Bt Cry毒素人工创制(“Bt toxin modification for enhanced efficacy”,Toxins,2014年,6卷第10期);而近年来,依托抗体“网络免疫学说”中Ab2β抗独特型抗体具备模拟抗原部分结构和生物功能的特性为理论依据(“Internal image(Ab2β)anti-idiotypevaccines:Theoretical and practical aspects”,Vaccine,1991年,9卷第11期),以BtCry毒素抗体为靶标,从噬菌体展示抗体库中靶向筛选具备模拟Bt Cry毒素抗虫功能的Ab2β抗独特型抗体(“Bt Cry毒素抗虫模拟物靶向创新设计”,生物工程学报,2023年,39卷第2期),已成为创制Bt Cry毒素功能效应物的全新路径,但该方法在模拟功效上仍然差强人意。
发明人团队前期在Bt Cry毒素共性结构和功能分析研究中,通过比较7种Bt Cry毒素(Cry1Aa、Cry1Ab、Cry1Ac、Cry1B、Cry1C、Cry1E、Cry1F)的氨基酸序列信息,获得了3个初步具备模拟Bt Cry毒素部分结构和功能的共性结构短肽,氨基酸序列分别为:CSQRYRVRIRYAS(SEQ ID NO.5)、CSFREWEADPTNPALREEMRI(SEQ ID NO.6)和CSGTVDSLDEIPPQNNNV(SEQ ID NO.7)(“Production and Characterization ofMonoclonal Antibody Broadly Recognizing Cry1 Toxins by Use ofDesignedPolypeptide as Hapten”,2016年,Analytical chemistry,88卷第14期),但因这3个短肽分子量太小,既难以通过常规方式进行克隆表达与纯化制备,也无法将其作为免疫原直接用于免疫动物制备Bt Cry毒素广谱抗体,从而限制这些抗体的实际应用。
发明内容
针对Bt Cry毒素蛋白靶标害虫抗药性问题的新型替代生物抗虫材料和Bt Cry毒素蛋白农药制剂及其转基因作为的监管需求,探寻具备模拟Bt Cry毒素共性结构结构和功能的多肽材料,具体而言,本发明是这样实现的:
首先,本申请提供了一种具备模拟Bt Cry毒素共性结构和功能的多肽,其氨基酸序列如SEQ ID NO.2所示。
其次,本申请提供了上述具备模拟Bt Cry毒素共性结构和功能的多肽的编码基因,其核苷酸序列如SEQ ID NO.1所示。
第三,本申请还提供了氨基酸序列如SEQ ID NO.2所示的蛋白在防治靶标害虫棉铃虫中的应用。
第四,本申请提供了含有核苷酸序列为SEQ ID NO.1的重组表达载体、转基因细胞系或重组工程菌。
第五,本申请提供了氨基酸序列如SEQ ID NO.2所示的蛋白作为免疫原在制备BtCry毒素检测抗体中的应用,该Bt Cry毒素包括Cry1Ab、Cry1Ac、Cry1Ah、Cry1B、Cry1C、Cry1F中的至少一种。
本申请借鉴人源噬菌体展示单链抗体库重-轻链拼接技术(“Rapid isolation ofsingle-chain antibodies from a human synthetic phage display library fordetection of Bacillus thuringiensis(Bt)Cry1B toxin”,Ecotoxicology andenvironmental safety,2012年,总第81期),首次通过设计特异性Linker将3个具备模拟BtCry毒素部分结构和功能的共性结构短肽,串联拼接成为具备免疫原功能的大分子多肽(该多肽氨基酸序列如图6所示,其中下划线部分为本申请设计的linker),从而得到更具研究意义和应用价值的可模拟Bt Cry毒素抗虫功能以及替代其作为免疫原用于免疫制备BtCry毒素广谱抗体的新型多肽材料。
本发明从公开的Bt毒素信息数据库信息中,通过比较7种Bt Cry毒素(Cry1Aa、Cry1Ab、Cry1Ac、Cry1B、Cry1C、Cry1E、Cry1F)的氨基酸序列信息,所获得了3个初步具备模拟Bt Cry毒素部分结构和功能的共性结构短肽,这三个短肽的氨基酸序列分别如SEQ IDNO.5-SEQ ID NO.7所示。由于用于串联的三个短肽是α螺旋,属跨膜蛋白,会干扰宿主表达菌细胞活性,表达制备较为困难。申请人构建和测试了5套表达系统(包括pGEX-6P载体、pET26b载体、pET28a载体、pIT2噬菌粒载体、pSUMO-Mut载体),最终通过设计的特异性Linker在pSUMO-Mut表达载体和宿主菌中成功制备出了该多肽蛋白。首次将这3个短肽串联拼接成为全新的可模拟Bt Cry毒素共性结构和功能且具备免疫原性的长链多肽。经委托公司合成,获得该多肽对应基因序列。该多肽通过原核系统表达,纯化后的蛋白对Bt Cry毒素靶标害虫棉铃虫钙黏蛋白受体具有良好结合活性且该多肽与靶标害虫受体的结合活性均明显高于三个原始短肽,并对供试棉铃虫具有良好杀虫活性,此外以该多肽蛋白作为免疫原免疫小鼠后制备的血清能同时识别供试的6种Bt Cry毒素(Cry1Ab、Cry1Ac、Cry1Ah、Cry1B、Cry1C、Cry1F)。
与现有技术相比,本申请具有以下有益效果:
1、本申请创制的多肽材料具备Bt Cry毒素共性结构(命名为Bt Cry-GXJG-11)特征和初步模拟其生物活性功能,该多肽在结构上与任一个原始短肽共性结构相比,拥有更大程度的Bt Cry毒素特征性共性结构,因此在模拟Bt Cry毒素结构和功能上具备潜在的更大可能性和优势。
2、本申请的多肽属大分子,具备免疫原性,可直接作为免疫原免疫动物制备BtCry毒素检测用广谱抗体,而三个原始个短肽由于是小分子,不具备免疫原性,因此不能作为免疫原直接免疫动物制备抗体,必须要额外偶联一个大分子载体蛋白才能作为免疫原用于免疫动物制备抗体,显然申请的多肽较上述3个短肽在制备目的抗体上更为方便和高效。在Bt Cry毒素靶标害虫绿色防治和Bt Cry毒素检测用广谱抗体研发上具有直接或潜在应用价值,为进一步研发Bt Cry毒素杀虫功能的新型模拟物以及为制备Bt Cry毒素检测用广谱抗体的创新免疫原奠定了材料基础。
3、本申请的多肽可直接作为包被抗原从噬菌体展示基因工程抗体库中淘筛获得Bt Cry毒素广谱检测用基因工程抗体,而3个原始短肽显然不具备该应用。
附图说明
图1为Bt Cry-GXJG-11基因克隆过程PCR电泳结果示意图;
其中,A为Bt Cry-GXJG-11基因PCR电泳结果,M:DNAMarker;1:Bt Cry-GXJG-11基因核苷酸片段;
B为pSUMO-Mut-Bt Cry-GXJG-11重组质粒化转E.coli BL21感受态细胞后的菌落PCR电泳检测结果,M:DNAMarker;CK:空载对照;1~6:重组质粒化转感受态细胞后随机单菌落PCR电泳检测结果。
图2为Bt Cry-GXJG-11蛋白原核表达与蛋白纯化验证图;
其中,A:为Bt Cry-GXJG-11蛋白诱导表达培养物SDS-PAGE分析结果;M:蛋白Marker;泳道1-5分别为pSUMO-Mut空载培养液、阳性克隆菌未加诱导剂的培养液、阳性克隆菌诱导表达培养液、阳性克隆菌诱导表达培养上清液、阳性克隆菌诱导表达离心沉淀超声裂解液;
B为Bt Cry-GXJG-11诱导表达蛋白纯化SDS-PAGE分析结果;M:蛋白Marker;泳道1-2均为阳性克隆菌诱导表达培养上清液,泳道3-5均为阳性克隆菌诱导表达培养上清液过柱纯化后250mM咪唑洗脱收集液;
C为Bt Cry-GXJG-11纯蛋白Western Blot分析结果。
图3为Bt Cry-GXJG-11蛋白竞争ELISA和分子互作分析图;
其中,A为Bt Cry-GXJG-11蛋白与棉铃虫HaCad-TBR受体的竞争抑制ELISA曲线;
B为Bt Cry-GXJG-11蛋白与棉铃虫HaCad-TBR受体互作的结合解离曲线,其中1为浓度为10μM的Bt Cry-GXJG-11蛋白溶液,2~4为浓度分别为0.25、0.125和0μM的Cry1Ac毒素溶液对照。
图4为Bt Cry-GXJG-11蛋白抗虫生测效果图。
图5为小鼠血清ELISA检测结果示意图;
其中,A为Bt Cry-GXJG-11蛋白免疫小鼠血清对供试Bt Cry毒素的ELISA显色图;B为Bt Cry-GXJG-11蛋白首轮免疫小鼠血清对供试Bt Cry毒素的ELISA曲线;C为Bt Cry-GXJG-11蛋白第二轮免疫小鼠血清对供试Bt Cry毒素的ELISA曲线。
图6为Bt Cry-GXJG-11多肽的氨基酸序列及linker示意图。
具体实施方式
实施例中所涉及的试剂和培养基配方:
(1)TB液体培养基:
在天平上称取11.8g胰蛋白胨、23.6g酵母提取物,加900mL去离子水溶解,加入5mL80%甘油(预先配制),115℃高压蒸汽灭菌20分钟,待培养基冷却到60℃以下时,倒入预制硫酸盐溶液即可。
预制磷酸盐溶液:在天平上称取9.4g K2HPO4、2.2g KH2PO4,用100mL去离子溶解,115℃高压蒸汽灭菌20分钟,室温冷却备用。
(2)TB固体培养基:
在上述TB液体培养基中加入含3%的琼脂粉。
(3)PBS溶液
称取NaCl 8g,KCl 0.2g,Na2HPO4·12H2O 2.9g,KH2PO40.2 g,分别加入到蒸馏水中,充分溶解后,定容到1L。
(4)PBST溶液
在PBS溶液中加入体积比为0.05%的吐温-20。
(5)四甲基联苯胺(TMB)溶液:
称取10mg四甲基联苯胺溶于1ml二甲基亚砜中,避光,置于4℃保存备用。
(6)底物显色溶液:
10ml配方成分:9.875ml CPBS、100μl TMB溶液、25μl体积比为20%H2O2。
(7)IPTG溶液
1ml体系:称取0.238g(1mM)IPTG溶于1ml蒸馏水中,配置成浓度为1mM/ml的母液,于-20℃保存备用。
(8)PBS溶液
1L体系:氯化钠8g、氯化钾0.2g、十二水合磷酸氢二钠2.9g、磷酸二氢钾0.2g,由双蒸水定容至1L;121℃灭菌20min,室温保存备用。该溶液为常规试剂,对供试虫子无致死作用。
(9)固体饲料
1L体系:生小麦胚芽46.17g、干酪素33.24g、蔗糖35.61g、山梨酸钾1.06g、纤维素6.6g、苯甲酸甲酯1.43g、链霉素1g、抗坏血酸3.7g、琼脂25g,由超纯水定容至1L。该固体饲料是植保领域饲养害虫常见饲料,对供试虫子无致死作用。
实施例中所涉及材料来源:
供试Bt Cry毒素共性结构串联多肽(申请人将该多肽自命名为Bt Cry-GXJG-11),基因序列委托通用生物(安徽)股份有限公司合成;
pSUMO-Mut表达载体、E.coli BL21感受态细胞购于北京全式金生物技术有限公司;Bt Cry毒素(Cry1Ab、Cry1Ac、Cry1Ah、Cry1B、Cry1C、Cry1F)购于美延(北京)农业科技有限责任公司;
供试靶标害虫棉铃虫3龄幼虫以及棉铃虫HaCad-TBR受体蛋白由省部共建国家重点实验室-江苏省食品质量安全重点实验室饲养和制备提供;
供试Balb/c模式实验小白鼠有扬州大学比较医学中心提供。
实验试剂:EcoRV/XhoI核酸内切酶、T4 DNA连接酶、PCR纯化试剂盒、质粒提取试剂盒、卡那霉素(Kana)、IPTG诱导剂购于日本Takara公司;
Anti His-Tag(HRP)鼠源单克隆抗体、Goat anti-mouse IgG-HRP单克隆抗体、Biosharp BL741A预染蛋白Marker购于北京擎科生物科技有限公司;
TMB底物显色液、ECL显色液、PVDF膜购于北京普利莱基因技术有限公司;其他试剂均为分析纯。
实施例中涉及的核苷酸序列和氨基酸序列:
SEQ ID NO.1:
TGCAGTCAGCGCTATCGTGTTCGTATTCGTTATGCAAGCGGCGGCGGTGGTAGCTGTAGTTTTCGCGAATGGGAAGCAGATCCGACCAATCCGGCACTGCGCGAAGAAATGCGTATTGGTGGCGGTGGCAGCTGTAGTGGTACCGTGGATAGTCTGGATGAAATTCCGCCGCAGAATAATAATGTTGGTGGCGGCGGCAGTGGTGGCGGTGGTAGTGGTGGCGGCGGTAGCGGTGGTGGCGGTTCATGCAGTCAGCGTTATCGCGTGCGCATTCGTTATGCGAGCAGTGGCGGTGGCGGCAGCTGCAGTTTTCGTGAATGGGAAGCCGATCCGACCAACCCGGCACTGCGTGAAGAAATGCGCATTGGTGGCGGCGGAAGTTGTAGTGGTACAGTGGATAGCCTGGATGAAATCCCGCCGCAGAACAATAATGTT。
SEQ ID NO.2:
CSQRYRVRIRYASGGGGSCSFREWEADPTNPALREEMRIGGGGSCSGTVDSLDEIPPQNNNVGGGGSGGGGSGGGGSGGGGSCSQRYRVRIRYASSGGGGSCSFREWEADPTNPALREEMRIGGGGSCSGTVDSLDEIPPQNNNV。
SEQ ID NO.3:
TGAGGCTCACCGCGAACAGATTGGAGGCTGCAGTCAGCGCTATCGTGTTCGTATTCGTTATGCAA。
SEQ ID NO.4:
TTTGTTAGCAGCCGGATCTCAGGTGCTCGAGTTAAACATTATTGTTCTGCGGCGGGATTTCATCC。
实施例1Bt Cry-GXJG-11基因克隆
委托公司合成Bt Cry-GXJG-11基因(其核苷酸序列如SEQ ID NO.1所示),并将该基因克隆到pGEX-6P-1质粒载体中,构建pGEX-6P-1-Bt Cry-GXJG-11重组质粒,进而导入到大肠杆菌BL21中,过夜培养到对数生长期(菌液浓度为108CUF/ml)。同时针对该Bt Cry-GXJG-11基因设计特异性上游引物I(其核苷酸序列如SEQ ID NO.3所示)和下游引物II(其核苷酸序列如SEQ ID NO.4所示),以扩增目的基因。
PCR扩增体系(20μL):含2×Trq Mix 10μL、菌液1μL、浓度为0.5μM的引物I 0.5μL、浓度为0.5μM的引物II 0.5μL,ddH2O补足余量。
PCR扩增条件为:首先94℃预变性10min,接着94℃变性1min、56℃退火1min、72℃延伸1min,共30个循环反应,最后72℃延伸10min。
PCR产物以质量百分数为1.5%的琼脂糖凝胶电泳分析目的条带状况(电泳结果如图1中A所示),最后借助PCR产物纯化试剂盒纯化目的片段。
然后取纯化后的Bt Cry-GXJG-11基因片段和pSUMO-Mut载体分别以EcoRV和XhoI核酸内切酶进行双酶切,借助PCR产物纯化试剂盒纯化回收相应酶切产物,并按目的基因浓度与载体片段浓度1:5的比例进行酶连过夜。次日以42℃热激90s条件将酶连体系化转到E.coli BL21感受态细胞中,接着涂布到于含终浓度为50μg/mL Kana的TB固体培养基上,置于37℃恒温培养箱中过夜培养。从培养板中随机挑取长出的单克隆菌落接种到含终浓度为50μg/mL Kana的TB液体培养基中,在37℃摇床中以220rpm振荡培养过夜。次日取培养菌液分别采用目的基因PCR扩增(扩增方法同上)、目的片段测序等方式进行综合鉴定,PCR扩增结果如图1中B所示。
由图1可见,Bt Cry-GXJG-11基因在特异性引物PCR扩增后,产物经琼脂糖凝胶电泳,在450bp左右出现了与预期目的DNA分子量大小相当的目的条带(如图1中A所示),说明PCR扩增成功(Bt Cry-GXJG-11多肽为145个氨基酸,对应基因是435个核苷酸bp,以及pGEX-6P-1载体质粒多克隆位点前后通用引物序列及多克隆位点序列约50bp,因此PCR产物全长在500bp左右,与图示相符)。
经PCR产物回收试剂盒纯化、酶切、酶连等步骤,构建的pSUMO-Mut-Bt Cry-GXJG-11重组质粒载体化转到E.coli BL21感受态细胞中,在抗性筛选培养基上涂布长出的阳性单菌落,经特异性引物PCR扩增,其在琼脂糖凝胶上出现了与预期目的DNA分子量大小相当的DNA条带,如图1中B所示,(Bt Cry-GXJG-11基因是435bp,以及pSUMO-Mut-载体质粒多克隆位点前后通用引物序列及多克隆位点序列约390bp,因此PCR产物全长在830bp左右,与图示相符)。结合测序结果与SEQ ID NO.1所述核苷酸序列一致,证实pSUMO-Mut-Bt Cry-GXJG-11重组质粒克隆并化转成功,可用于后期目的蛋白诱导表达。
实施例2Bt Cry-GXJG-11蛋白原核表达与纯化
挑取实施例1经鉴定为Bt Cry-GXJG-11基因克隆阳性的单克隆菌液接种到含终浓度为50μg/mL Kana的TB液体培养基中,在37℃摇床中以220rpm振荡培养过夜。次日将培养菌液按1:1000转接到含终浓度为50μg/mL Kana的TB液体培养基中,在37℃摇床中以220rpm振荡培养至对数生长期(约2.5h),接着向体系中加入终浓度为0.2M IPTG诱导剂,随后将温度调至15℃,诱导表达16h。取出诱导培养体系置于4℃预冷的离心机中,以8000g离心10min,弃上清液后,取沉淀细胞以30mL PBS重悬。取出重悬体系,借助超声波细胞破碎仪按“每工作1s,间隙2.5s”程序持续超声30min,进行全细胞超声裂解。裂解液置于事先预冷的4℃离心机中,以8000g离心20min,收集上清液(即含Bt Cry-GXJG-11目的蛋白),借助12%SDS-PAGE对收集液跑胶后,采用考马斯亮蓝对目的蛋白进行染色分析。按照商品化的His-Trap(HP)亲和纯化柱产品操作手册描述的步骤,对含有Bt Cry-GXJG-11目的蛋白的收集液进行过柱和洗脱纯化,最终收集获得目的蛋白采用Western-Blot法进行鉴定和分析,其检测结果如图2所示。
由图2可见,经鉴定为阳性的pSUMO-Mut-Bt Cry-GXJG-11重组质粒化转菌接种到含Kana的TB液体培养基中,在15℃和220rpm培养条件下,以终浓度为0.2M IPTG诱导表达16h,收集的诱导表达上清液经SDS-PAGE电泳后,在35KD左右出现了与预期目的蛋白分子量大小相当的目的条带(如图2中A所示)。该诱导表达上清液经His-Trap(HP)亲和纯化柱梯度洗脱和纯化回收,并用PBS进行透析过夜,结合SDS-PAGE电泳结果(如图2中B所示)和Western Blot检测结果(如图2中C所示),综上确定制备获得了Bt Cry-GXJG-11纯蛋白,其在洗脱液缓冲液中的浓度为0.5mg/mL。
实施例3Bt Cry-GXJG-11蛋白竞争ELISA和分子互作分析
竞争ELISA分析:浓度为10μg/mL的Cry1Ac毒素蛋白按100μL/孔包被到96孔酶标板中,置于4℃静置包被过夜。次日取出包被板,按200μL/孔的PBST缓冲液(PBS缓冲液中含终浓度为0.05%Tween 20)洗板3次,接着按200μL/孔的MPBS封闭液(PBS缓冲液中含终浓度为4%脱脂奶粉)在37℃恒温培养箱中进行封闭2h,然后再以PBST缓冲液洗涤。随即按梯度顺序,每孔加入100μL浓度为10μg/mL的棉铃虫HaCad-TBR受体蛋白与浓度为10μg/mL的系列梯度浓度(200、100、50、25、10、5、1、0μL)的Bt Cry-GXJG-11蛋白溶液预混复合液,置于37℃恒温培养箱中孵育1h,取出孵育板,以PBST缓冲液洗涤后,每孔加入100μL以PBS溶液按1:5000稀释的商品化Anti His-Tag(HRP)鼠源单克隆抗体,并置于37℃恒温培养箱中再次孵育1h。取出孵育板,以PBST缓冲液洗涤后,每孔加入100μL TMB显色液,在室温避光反应15min,直至显色,最后每孔加入50μL浓度为2M H2SO4溶液终止反应,在酶标板中测定各孔的OD450值,绘制竞争抑制率曲线,如图3中A所示。
分子互作分析:将实施例2纯化出的蛋白样品与棉铃虫HaCad-TBR进行分子互作,通过传感器芯片实时检测它们相互作用的整个过程。选用APS探针,PBS中浸泡10min。分别配置0.1%和10%的BSA溶液,将PBS、BSA溶液、HaCad受体和蛋白样品每孔220μL包被96孔板(包被顺序为PBS、HaCad、0.1%BSA、Bt Cry-GXJG-11蛋白/Cry1Ac、0.1%BSA)。选择参数:Baseline、Loading、Baseline2、Association、Disassociation,运行后通过分析软件获取生物分子结合、解离常数等,验证结果如图3中B所示。
由图3可见,将Cry1Ac毒素作为包被原,然后以制备的系列梯度浓度的Bt Cry-GXJG-11蛋白作为竞争抑制物,抑制靶标害虫棉铃虫HaCad-TBR受体蛋白与Cry1Ac毒素结合,建立竞争抑制ELISA。如图3中A所示,Bt Cry-GXJG-11蛋白能与Cry1Ac毒素靶标害虫棉铃虫HaCad-TBR受体蛋白产生特异性结合反应,从而抑制其与Cry1Ac毒素结合;由此说明BtCry-GXJG-11蛋白在空间结构上与Bt Cry毒素具有相似之处。同时借助Octet蛋白质互作分析仪,通过生物膜干涉法测定了Bt Cry-GXJG-11蛋白与靶标害虫棉铃虫HaCad-TBR受体的结合能力以及互作的动力学过程,结果如图3中B所示;可见Bt Cry-GXJG-11蛋白对棉铃虫HaCad-TBR受体蛋白具有良好结合能力,其亲和力常数(KD)值达到2.151×10-7M,这也进一步证实Bt Cry-GXJG-11蛋白具备模拟Bt Cry毒素结构的功能。
实施例4Bt Cry-GXJG-11蛋白抗虫活性测定
取实施例2制备的1mL浓度为10μg/mL(以PBS溶液稀释)的Bt Cry-GXJG-11蛋白溶液均匀涂布到含有固体饲料培养皿上,置于室温晾干后,每个培养皿挑入20头处于3龄幼虫阶段的棉铃虫(常规非抗性品系,即敏感品系),在室温条件下进行室内生测饲养实验。每24h记录一次培养皿中供试虫子的生长发育状态,每个处理组重复3次实验,结果如图4所示。
图4为实验第三天(72h)的虫子状态,由图4可见,以浓度为10μg/mL的Bt Cry-GXJG-11蛋白溶液作为测试药剂,供试的棉铃虫幼虫在取食浸有该药剂的饲料后显示,校正死亡率达到27.5%,且致死虫体的表观状态与取食Bt Cry毒素类似(如文献“路献勇等,3种Bt蛋白对棉铃虫敏感品系致死作用研究,中国棉花.2013,40(09)”所公开敏感品系喂食BtCry毒素的表观)。
实施例5Bt Cry-GXJG-11蛋白免疫效果测定
首先将实施例2制备的100μL制备的浓度为100μg/mL(以PBS溶液稀释)Bt Cry-GXJG-11蛋白溶液与150μL完全弗氏佐剂混匀并进行充分乳化后,以腹腔注射免疫的方式,将其注射到六周龄的Balb/c模式实验小白鼠体内。饲养两周后,将100μL浓度为100μg/mLBt Cry-GXJG-11蛋白溶液与150μL不完全弗氏佐剂混匀并进行充分乳化后,同样采用腹腔免疫方式注射到供试小鼠体内;再饲养两周后,将100μL浓度为100μg/mL Bt Cry-GXJG-11蛋白溶液与150μL不完全弗氏佐剂混匀并进行充分乳化后,接着采用腹腔免疫方式注射到供试小鼠体内。饲养两周后,从供试小鼠尾部抽取血液(约50μL)用于ELISA法测(A highlyspecific immunoassay for microcystin-LR detection based on amonoclonalantibody,Sheng等,Analytica Chimica Acta,2007,603卷第1期)定其免疫效果,其结果如图5中A所示,ELISA曲线如图5中B所示。
参照上述竞争ELISA法描述步骤,分别将浓度为10μg/mL的Cry1Ab、Cry1Ac、Cry1Ah、Cry1B、Cry1C、Cry1F毒素蛋白按100μL/孔包被到96孔酶标板中,经过“洗涤-封闭-再洗涤”步骤,将采集获得的供试小鼠血清梯度稀释液(以PBS溶液按10倍稀释法进行稀释)以100μL/孔加入到包被板中,经过“孵育-洗涤”过程,每孔加入100μL以PBS溶液按1:5000稀释的商品化Goat anti-mouse IgG-HRP单克隆抗体,再经过“孵育-洗涤-显色-终止”过程,测定各孔的OD450值,绘制ELISA反应曲线,如图5中C所示。
由图5可见,以Bt Cry-GXJG-11蛋白溶液为免疫原,经2轮免疫过后,采集的供试小鼠血清对Cry1Ab、Cry1Ac、Cry1Ah、Cry1B、Cry1C和Cry1F这6种供试的Bt Cry毒素具有较强广谱识别能力(如图5中A所示),其中对Cry1Ah结合能力最强,效价达到2×104,而对Cry1Ab结合能力相对较弱,效价为1×103(如图5中B/C所示)。由此证明,多肽Bt Cry-GXJG-11具有模拟Bt Cry毒素结构和抗虫活性的功能,该多肽可以替代Bt Cry毒素作为免疫原,制备BtCry毒素检测用广谱抗体,进而为Bt Cry毒素检测提供高效的广谱抗体材料。
Claims (5)
1.一种模拟Bt Cry毒素共性结构和功能的多肽,其氨基酸序列如SEQ ID NO.2所示。
2.如权利要求1所述模拟Bt Cry毒素共性结构和功能的多肽的编码基因,其核苷酸序列如SEQ ID NO.1所示。
3.含有如权利要求2所述编码基因的重组表达载体、转基因细胞系或重组工程菌;所述转基因细胞系为非植物细胞系。
4.如权利要求1所述多肽在杀灭棉铃虫中的应用。
5.如权利要求1所述多肽作为免疫原在制备Bt Cry毒素抗体中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310192513.6A CN116178512B (zh) | 2023-03-02 | 2023-03-02 | 一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310192513.6A CN116178512B (zh) | 2023-03-02 | 2023-03-02 | 一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116178512A CN116178512A (zh) | 2023-05-30 |
CN116178512B true CN116178512B (zh) | 2024-03-19 |
Family
ID=86438129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310192513.6A Active CN116178512B (zh) | 2023-03-02 | 2023-03-02 | 一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116178512B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679491A (zh) * | 2007-03-28 | 2010-03-24 | 先正达参股股份有限公司 | 杀虫的蛋白质 |
CN104861074A (zh) * | 2015-04-14 | 2015-08-26 | 中国农业科学院作物科学研究所 | 融合杀虫蛋白Cry1Am、其编码基因及应用 |
CN105624177A (zh) * | 2016-02-04 | 2016-06-01 | 浙江大学 | 一种抗虫融合基因、编码蛋白、载体及其应用 |
CN105777899A (zh) * | 2016-04-25 | 2016-07-20 | 江苏省农业科学院 | 抗Bt Cry1Ab毒素单克隆抗体及产生该抗体的细胞株、制备方法与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098051A1 (en) * | 2007-07-11 | 2009-04-16 | Ibrahim Mohamed A | Bacillus thuringiensis toxin |
CN108997495B (zh) * | 2018-08-09 | 2020-08-07 | 江苏省农业科学院 | 一种改进的人源模拟Bt Cry杀虫蛋白功能效应物及其设计方法与应用 |
-
2023
- 2023-03-02 CN CN202310192513.6A patent/CN116178512B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679491A (zh) * | 2007-03-28 | 2010-03-24 | 先正达参股股份有限公司 | 杀虫的蛋白质 |
CN104861074A (zh) * | 2015-04-14 | 2015-08-26 | 中国农业科学院作物科学研究所 | 融合杀虫蛋白Cry1Am、其编码基因及应用 |
CN105624177A (zh) * | 2016-02-04 | 2016-06-01 | 浙江大学 | 一种抗虫融合基因、编码蛋白、载体及其应用 |
CN105777899A (zh) * | 2016-04-25 | 2016-07-20 | 江苏省农业科学院 | 抗Bt Cry1Ab毒素单克隆抗体及产生该抗体的细胞株、制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
Bt Cry1类毒素共性结构域的分析、表达及鉴定;刘贝贝;张霄;谢雅晶;焦凌霞;刘媛;张存政;赵岩岩;武爱华;刘贤金;;中国农业科学(16);第3130-3139页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116178512A (zh) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103773774B (zh) | 一种人源抗虫基因及其编码的抗Cry1Ab毒素独特型单链抗体与应用 | |
CN103773775B (zh) | 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用 | |
EP3067423B1 (en) | Human insecticidal gene and insecticidal peptide encoded thereby, and use thereof | |
Xu et al. | Construction of an immunized rabbit phage display library for selecting high activity against Bacillus thuringiensis Cry1F toxin single-chain antibodies | |
US9745385B2 (en) | Anthropogenic insect-resistant gene and Cry1C toxin idiotype single-chain antibody encoded thereby and application thereof | |
Xu et al. | Establishment of a sensitive time-resolved fluoroimmunoassay for detection of Bacillus thuringiensis Cry1Ie toxin based nanobody from a phage display library | |
CN114292820A (zh) | 抗虫蛋白Cry 3Bb杂交瘤细胞株及其产生的抗体和应用 | |
Xu et al. | Selection and application of broad-specificity human domain antibody for simultaneous detection of Bt Cry toxins | |
CN116178512B (zh) | 一种模拟Bt Cry毒素共性结构和功能的多肽及其编码基因与应用 | |
Dong et al. | Screening of anti-idiotypic domain antibody from phage library for development of Bt Cry1A simulants | |
Zhong et al. | Broad specificity immunoassay for detection of Bacillus thuringiensis Cry toxins through engineering of a single chain variable fragment with mutagenesis and screening | |
CN105884892B (zh) | 一种Bt Cry毒素广谱检测用蛋白及其编码基因与应用 | |
Hao et al. | Screening and activity identification of an anti-idiotype nanobody for Bt Cry1F toxin from the camelid naive antibody phage display library | |
CN111337687A (zh) | 昆虫钙黏蛋白含量酶联免疫定量检测试剂盒及其使用方法 | |
Lin et al. | Anti-idiotypic single-chain variable fragment antibody partially mimic the functionally spatial structure of Cry2Aa toxin | |
CN113754762B (zh) | 一种抗Cry3Bb蛋白单域重链抗体及其应用 | |
CN113512115A (zh) | 一种广谱识别小菜蛾中肠受体的抗Cry2Aa独特型单域抗体及其应用 | |
CN105085683A (zh) | 一种具有杀虫活性的猪源化改型抗体及其制备方法与应用 | |
Xu et al. | Targeting Design of Human Anti-idiotypic Genetically Engineered Antibody for Simulating the Structure and Insecticidal Function of Bt Cry1C Toxin | |
Lin et al. | Generation of anti-idiotypic antibodies mimicking Cry2Aa toxin from an immunized mouse phage display library as potential insecticidal agents against Plutella xylostella | |
CN112940116B (zh) | 单域抗体、重组抗体、编码基因及制备方法和应用 | |
CN118745221A (zh) | 一种Bt Cry毒素广谱检测单克隆抗体及应用 | |
CN118930646A (zh) | 一种具备模拟Bt Cry1C毒素结构和杀虫功能的人源基因工程抗体及其突变体 | |
CN105907693A (zh) | 一株表达抗黄绿青霉素的基因工程单链抗体株及其应用 | |
CN105131123A (zh) | 一种具有杀虫活性的牛源化改型抗体及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |